MA33691B1 - Schema posologique d'un modulateur des récepteurs de s1p - Google Patents

Schema posologique d'un modulateur des récepteurs de s1p

Info

Publication number
MA33691B1
MA33691B1 MA34805A MA34805A MA33691B1 MA 33691 B1 MA33691 B1 MA 33691B1 MA 34805 A MA34805 A MA 34805A MA 34805 A MA34805 A MA 34805A MA 33691 B1 MA33691 B1 MA 33691B1
Authority
MA
Morocco
Prior art keywords
treatment plan
receptor modules
receptor
modules
sphingosine
Prior art date
Application number
MA34805A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Craig Boulton
Pascale Burtin
Olivier David
Vera Ana De
Thomas Dumortier
Irene Hunt
Robert Schmouder
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43759693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33691(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33691B1 publication Critical patent/MA33691B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/021—Measuring pressure in heart or blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/024—Measuring pulse rate or heart rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/444—Evaluating skin marks, e.g. mole, nevi, tumour, scar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4833—Assessment of subject's compliance to treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
MA34805A 2009-09-29 2012-04-26 Schema posologique d'un modulateur des récepteurs de s1p MA33691B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24670609P 2009-09-29 2009-09-29
US25832909P 2009-11-05 2009-11-05
US30799210P 2010-02-25 2010-02-25
US35202910P 2010-06-07 2010-06-07
PCT/US2010/049441 WO2011041146A2 (en) 2009-09-29 2010-09-20 Dosage regimen of an s1p receptor modulator

Publications (1)

Publication Number Publication Date
MA33691B1 true MA33691B1 (fr) 2012-10-01

Family

ID=43759693

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34805A MA33691B1 (fr) 2009-09-29 2012-04-26 Schema posologique d'un modulateur des récepteurs de s1p

Country Status (18)

Country Link
US (8) US20120264719A1 (enExample)
EP (4) EP3047848A1 (enExample)
JP (5) JP2013505983A (enExample)
KR (1) KR20120083442A (enExample)
CN (2) CN102548579A (enExample)
AU (2) AU2010101513B4 (enExample)
BR (1) BR112012006957A2 (enExample)
CA (2) CA2773330C (enExample)
IL (2) IL218486A0 (enExample)
MA (1) MA33691B1 (enExample)
MX (1) MX2012003740A (enExample)
NZ (1) NZ598534A (enExample)
PH (2) PH12012500520A1 (enExample)
RU (1) RU2012117563A (enExample)
SG (4) SG10201406168RA (enExample)
TN (1) TN2012000104A1 (enExample)
WO (1) WO2011041146A2 (enExample)
ZA (2) ZA201201678B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201406168RA (en) * 2009-09-29 2014-11-27 Novartis Ag Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
JO3619B1 (ar) 2011-01-07 2020-08-27 Novartis Ag صياغات مثبطة للمناعة
DK2675893T3 (en) 2011-02-18 2019-04-15 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
US8889627B2 (en) * 2011-10-12 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
SG11201401065RA (en) * 2011-10-21 2014-09-26 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
AU2013385181A1 (en) 2013-04-04 2015-08-27 Novartis Ag Identifying patient response to S1P receptor modulator administration
WO2015155709A1 (en) * 2014-04-10 2015-10-15 Novartis Ag S1p modulator immediate release dosage regimen
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
CA3086037A1 (en) 2017-11-30 2019-06-06 Viewmind S.A. System and method for detecting neurological disorders and for measuring general cognitive performance
JP2022529474A (ja) * 2019-04-17 2022-06-22 ペア セラピューティクス （ユーエス）、インコーポレイテッド デジタル療法を利用する抑鬱症状、抑鬱障害の処置のための電子デバイスおよび方法
WO2021158845A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158847A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158838A1 (en) 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
WO2021158844A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158841A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158839A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158843A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
IL298996A (en) * 2020-06-11 2023-02-01 Univ Columbia Methods and preparations for the prevention and treatment of myopia (myopia) with pingolimod, a sphingosine-1-phosphate receptor modulator, and their derivatives
JP2025526449A (ja) * 2022-07-28 2025-08-13 ヴューマインド インコーポレイテッド 特定の薬品又は治療が視覚処理、認知機能、及び関連する脳の活動を向上させるであろう、特定の視覚的刺激を使用する際の眼球運動パターンを分析する、定義された疾病を有する被験者の特定の変化を識別する方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231560B1 (en) * 1999-02-10 2001-05-15 Baxter International Inc Method and apparatus for automatically controlling the level of medication
GB0211261D0 (en) * 2002-05-16 2002-06-26 Novartis Ag Organic compounds
BR0311173A (pt) 2002-05-16 2005-03-15 Novartis Ag Uso de agentes de ligação do receptor de edg em câncer
WO2004080446A1 (en) * 2003-03-14 2004-09-23 Agi Therapeutics Ltd. Treatment of intestinal conditions with n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine
EP1644367B1 (en) 2003-05-19 2015-10-14 Novartis AG Immunosuppressant compounds and compositions
US20050090520A1 (en) * 2003-09-12 2005-04-28 Per Lindquist Treatment of disease or injury of the nervous system with FTY720
US7127355B2 (en) * 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
KR20130041385A (ko) 2004-11-29 2013-04-24 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
JP2007061274A (ja) * 2005-08-30 2007-03-15 Transcutaneous Technologies Inc センサからの副作用情報による投薬停止システムを備えたイオントフォレーシス装置
EP1923058A1 (en) 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
KR20110020928A (ko) 2008-06-20 2011-03-03 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
SG171404A1 (en) 2008-12-22 2011-07-28 Novartis Ag Dosage regimen for a s1p receptor agonist
SG10201406168RA (en) * 2009-09-29 2014-11-27 Novartis Ag Dosage regimen of an s1p receptor modulator

Also Published As

Publication number Publication date
CN103933570A (zh) 2014-07-23
CN102548579A (zh) 2012-07-04
US20160256416A1 (en) 2016-09-08
SG10201902152XA (en) 2019-04-29
JP2016155840A (ja) 2016-09-01
US20180263930A1 (en) 2018-09-20
KR20120083442A (ko) 2012-07-25
AU2010101513B4 (en) 2016-05-05
JP7185426B2 (ja) 2022-12-07
JP2023093482A (ja) 2023-07-04
CA3129729A1 (en) 2011-04-07
IL250439A0 (en) 2017-03-30
US20170304226A1 (en) 2017-10-26
BR112012006957A2 (pt) 2016-06-14
JP2013505983A (ja) 2013-02-21
US20140187516A1 (en) 2014-07-03
US20230086687A1 (en) 2023-03-23
AU2010101513A6 (en) 2014-07-10
IL218486A0 (en) 2012-04-30
AU2010300919A1 (en) 2012-03-22
US11759436B2 (en) 2023-09-19
CA2773330A1 (en) 2011-04-07
JP2018172401A (ja) 2018-11-08
EP3061449A1 (en) 2016-08-31
EP3047848A1 (en) 2016-07-27
TN2012000104A1 (en) 2013-09-19
US20180263929A1 (en) 2018-09-20
SG10201913361RA (en) 2020-03-30
EP2482810A2 (en) 2012-08-08
MX2012003740A (es) 2012-04-30
WO2011041146A3 (en) 2011-06-03
PH12017501495A1 (en) 2018-07-02
WO2011041146A2 (en) 2011-04-07
SG178987A1 (en) 2012-04-27
SG10201406168RA (en) 2014-11-27
US20120264719A1 (en) 2012-10-18
NZ598534A (en) 2014-03-28
US20200222338A1 (en) 2020-07-16
RU2018118645A3 (enExample) 2021-09-13
PH12012500520A1 (en) 2012-10-22
AU2010101513A4 (en) 2014-06-26
RU2012117563A (ru) 2013-11-10
CA2773330C (en) 2021-11-02
US10543179B2 (en) 2020-01-28
RU2018118645A (ru) 2018-11-05
JP2020203892A (ja) 2020-12-24
EP3831371A1 (en) 2021-06-09
ZA201404270B (en) 2014-12-23
ZA201201678B (en) 2016-01-27

Similar Documents

Publication Publication Date Title
MA33691B1 (fr) Schema posologique d'un modulateur des récepteurs de s1p
EA201100978A1 (ru) Схема приема агониста рецептора s1p
CL2014000210A1 (es) Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion.
IN2014CN02616A (enExample)
MX2020010693A (es) Uso de peptidos glp-1 de accion prolongada.
CR20110142S (es) Manguito quirúrgico
EP2467566A4 (en) VALVE SEAT WITH SELF-ALIGNING SLUDGE SAVER
MX370264B (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
PL2709522T3 (pl) Układ do synergicznej neurofizjologicznej rehabilitacji i/lub rozwoju funkcjonalnego
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
GB201207975D0 (en) Improvements in or relating to pelvic reconstruction
TN2013000460A1 (en) Use of sigma ligands in diabetes type-2 associated pain
IL208386A0 (en) Lipid-oil-water nanoemulsion delivery system for microtubule-interacting agents
EP2684169A4 (en) TRANSACTION SYSTEM FOR MATCHING TWO SECURE PARTS
BRPI0822704A2 (pt) dispositivo para auxiliar um procedimento de parto.
CL2014001513A1 (es) Compuestos derivados de 6,7 -dihidro -5h-benzo-(7) anuleno, moduladores selectivos del receptor de estrogenos; un medicamento que comprenden a los mismos; y su uso como terapia de reemplazo hormonal masculino y femenino.
MX354818B (es) Moduladores del receptor x del higado.
ZA201402283B (en) Dosage regimen for an s1p receptor modulator or agonist
IN2012DE03426A (enExample)
FR2991431B1 (fr) Dispositif de fourniture de fluide sous pression
MX2010002032A (es) Uso de flibanserina para el tratamiento de sintomas vasomotores.
MX2014006255A (es) Tratamientos neurologiocos con metaloporfirina.
MX336979B (es) Combinacion farmaceutica antineuritica y composiciones.
MY161655A (en) Unit dosage of apadenoson
MX2014002693A (es) Uso de 1h-quinazolina-2,4-dionas para usarse en la prevencion o el tratamiento de epilepsia fotosensible.